Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shares reached a new 52-week high during trading on Thursday . Key Stories Impacting Replimune GroupHere are the key news stories impacting Replimune Group this week:Get Replimune Group alerts:Positive Sentiment: The FDA granted accelerated approval to Tudriqev (RP1/vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed after an anti-PD-1-based treatment. Replimune Group Stock PerformanceThe company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. Replimune Group Company Profile(Get Free Report)Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. Recommended StoriesReceive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.